Skip to main content

Increasing Knowledge to Improve Patient Outcomes in Multiple Myeloma

Recently, i3 Health provided an educational activity that has challenged knowledge gaps experienced by clinicians regarding practice-changing strategies for improved patient outcomes in multiple myeloma.   Multiple myeloma is a B-cell neoplasm characterized by aberrant expansion of plasma cells within the bone marrow and extramedullary sites. Approximately 35,780 new cases of multiple myeloma are expected to occur in the United States this year, and around 12,540 people are likely to die of...

Osimertinib Plus Platinum-Based Chemotherapy Approved for Locally Advanced or Metastatic Non–Small Cell Lung Cancer

The FDA has granted approval to osimertinib (Tagrisso®, AstraZeneca Pharmaceuticals LP) with platinum-based chemotherapy for patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.   Why it matters: "Osimertinib is a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) that is selective for EGFR...

Lifileucel Granted Accelerated Approval for Unresectable or Metastatic Melanoma

The FDA has granted accelerated approval to lifileucel (Amtagvi, Iovance Biotherapeutics, Inc.) for adult patients with unresectable or metastatic melanoma previously treated with a programmed cell death protein 1 (PD-1) blocking antibody, and if BRAF V600–positive, a BRAF inhibitor with or without a mitogen-activated protein kinase (MEK) inhibitor. Lifileucel is a tumor-derived autologous T-cell immunotherapy and is the first cellular therapy to receive an approval for solid tumors.   Why ...

Tepotinib Granted Traditional Approval for Metastatic Non–Small Cell Lung Cancer

The FDA has granted traditional approval to tepotinib (Tepmetko®, EMD Serono, Inc.) for adult patients with metastatic non–small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations. Tepotinib was previously granted accelerated approval for this indication on February 3, 2021.   Why it matters: "MET inhibitors have recently demonstrated clinical activity in patients with MET exon 14–skipping NSCLC; however, data with longer follow-up and in...

Addressing Knowledge Gaps in the Treatment of Advanced Endometrial Cancer

Recently, i3 Health provided an educational activity that has challenged knowledge gaps experienced by clinicians regarding emerging checkpoint inhibitor–based strategies for advanced endometrial cancer.   Cancer of the uterine corpus is the most common cancer of the female genital tract, with an estimated 67,880 new cases diagnosed and 13,250 deaths annually in the United States. Since more than 90% of cases occur in the endometrium, cancer of the uterine corpus is often referred to as end...

Irinotecan Liposome Approved for First-Line Metastatic Pancreatic Adenocarcinoma Treatment

The FDA has approved irinotecan liposome (Onivyde®, Ipsen Biopharmaceuticals, Inc.) with oxaliplatin, fluorouracil, and leucovorin, for the first-line treatment of metastatic pancreatic adenocarcinoma.   Why it matters: "The approval of liposomal irinotecan in combination with standard-of-care agents provides clinicians and patients with another option for first-line treatment of metastatic pancreatic cancer," wrote Joseph Kalis, PharmD, BCOP, an Ambulatory Oncology Pharmacy Specialist at t...

Racial and Socioeconomic Disparities in the CLL Community Oncology Setting With Ira Zackon, MD

Oncology Data Advisor® · Racial and Socioeconomic Disparities in the CLL Community Oncology Setting: Ira Zackon, MD At the recent 2023 American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor sat down with Ira Zackon, MD, a Senior Medical Director with Ontada, to discuss his abstract and presentation about racial and socioeconomic disparities experienced by patients in the chronic lymphocytic leukemia (CLL) community oncology and hematology setting, how to comba...

Real-World Outcomes of Brexucabtagene Autoleucel for Mantle Cell Lymphoma With Swetha Kambhampati, MD

Oncology Data Advisor® · Real-World Outcomes of Brexucabtagene Autoleucel for Mantle Cell Lymphoma: Swetha Kambhampati, MD At the recent American Society of Hematology (ASH) Annual Meeting, Swetha Kambhampati, an Assistant Professor in the Division of Lymphoma at City of Hope, sat down with Oncology Data Advisor to further discuss her presentationregarding real-world outcomes of brexucabtagene autoleucel (brexu-cel) in patients with relapsed/refractory mantle cell lymphoma.   Onc...

Exploring Acalabrutinib Plus or Minus Obinutuzumab for CLL in the ELEVATE-TN Study With Jeff Sharman, MD

Oncology Data Advisor® · Exploring Acalabrutinib ± Obinutuzumab for CLL in the ELEVATE-TN Study: Jeff Sharman, MD Recently, at the American Society of Hematology (ASH) Annual Meeting, Dr. Jeff P. Sharman, the Medical Director of Hematology Research for Sarah Cannon Research Institute and the US Oncology Network, presented the long-term follow up results from the ELEVATE-TN study, which investigated acalabrutinib plus or minus obinutuzumab for previously untreated patients with ...

Investigating Talquetamab Plus Pomalidomide in the MonumenTAL-2 Study With Jeffrey Matous, MD

Oncology Data Advisor® · Investigating Talquetamab + Pomalidomide in the MonumenTAL-2 Study: Jeffrey Matous, MD At the recent American Society of Hematology (ASH) Annual Meeting, Dr. Jeffrey Matous, MD, a Member of the Colorado Blood Cancer Institute in Denver, Colorado, presented his team's research and results of the MonumenTAL-2 trial, which studied talquetamab plus pomalidomide in patients with relapsed/refractory multiple myeloma. Dr. Matous then sat down with Oncology Data Advis...

Erdafitinib Approved for Locally Advanced or Metastatic Urothelial Cancer

The FDA has granted approval to erdafitinib (Balversa™, Janssen Biotech) for adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible fibroblast growth factor receptor 3 (FGFR3) genetic alterations, as determined by an FDA-approved companion diagnostic test, whose disease has progressed on or after at least one line of prior systemic therapy. Patients are not recommended to receive treatment with erdafitinib if they are eligible for and have not received pri...

Response Patterns of Linvoseltamab for Relapsed/Refractory Multiple Myeloma With Hans Lee, MD

Oncology Data Advisor® · Response Patterns of Linvoseltamab for Relapsed/Refractory Multiple Myeloma: Hans Lee, MD At the recent American Society of Hematology (ASH) Annual Meeting, Dr. Hans Lee, the Director of Multiple Myeloma Clinical Research at MD Anderson, presented his team's research from the LINKER-MM1 study, which sought to evaluate response patterns of linvoseltamab for relapsed/refractory multiple myeloma. Later, Dr. Lee sat down with Oncology Data Advisor to further discu...

Patterns of Care With BTK Inhibitors for CLL/SLL in the Community Setting With David Andorsky, MD

Oncology Data Advisor® · Patterns of Care With BTK Inhibitors for CLL/SLL in the Community Setting: David Andorsky, MD At the recent American Society of Hematology (ASH) Annual Meeting in San Diego, Dr. David Andorsky, MD, a Clinical Hematologist and Medical Oncologist at the Rocky Mountain Cancer Centers in Boulder, Colorado, presented his research and observations regarding patterns of care with Bruton tyrosine kinase (BTK) inhibitors and the distribution of social determinants of h...

Financial Hardship Experienced During Transplant in Myelodysplastic Syndromes With Christopher Su, MD

Oncology Data Advisor® · Financial Hardship Experienced During Transplant in Myelodysplastic Syndromes: Christopher Su, MD At the recent American Society of Hematology (ASH) Annual Meeting in San Diego, Christopher Su, MD, a Hematologist at the Fred Hutchinson Cancer Center, presented his research regarding financial hardships experienced in the transplant setting for myelodysplastic syndromes (MDS). Dr. Su then set down with Oncology Data Advisor to further discuss his study, the res...

Pembrolizumab Plus Chemoradiotherapy Approved for FIGO 2014 Stage III-IVA Cervical Cancer

The FDA has granted approval for pembrolizumab (Keytruda®, Merck) with chemoradiotherapy (CRT) for patients with International Federation of Gynecology and Obstetrics (FIGO) 2014 Stage III-IVA cervical cancer. For background: "Pembrolizumab has shown efficacy in patients with cervical cancer," said Domenica Lorusso, MD, PhD, an Associate Professor of Obstetrics and Gynecology at the Catholic University of Rome, and colleagues, in their updated results of the KEYNOTE-A18 trial (NCT04221945), on w...

Evaluating Outpatient Teclistamab Administration in Multiple Myeloma With Robert Rifkin, MD, FACP

Oncology Data Advisor® · Evaluating Outpatient Teclistamab Administration in Multiple Myeloma: Robert Rifkin, MD At the recent American Society of Hematology (ASH) Annual Meeting, Dr. Robert Rifkin, MD, FACP, a Board-Certified Medical Oncologist and Hematologist at the Rocky Mountain Cancer Centers in Denver, Colorado, sat down with Oncology Data Advisor to discuss his study and presentation on the OPTEC trial, in which administration of the bispecific antibody teclistamab will be eva...

Advancing Inclusion for Blood Donation Systems for Marginalized Groups With Warren Fingrut, MD

Oncology Data Advisor® · Advancing Inclusion for Blood Donation Systems for Marginalized Groups: Warren Fingrut, MD At the recent American Society of Hematology (ASH) Annual Meeting, Warren Fingrut, MD, a Transplant and Cell Therapy Physician at MD Anderson Cancer Center and Founder and Director of Stem Cell Club, a donor recruitment organization based in Canada, sat down with Oncology Data Advisor to discuss his team's research and presentation addressing disparities experienced by m...

Maintaining Functioning and Quality of Life With Odronextamab for Follicular Lymphoma: Benoit Tessoulin, MD

Oncology Data Advisor® · Maintaining Functioning and QOL With Odronextamab for Follicular Lymphoma: Benoit Tessoulin, MD At the recent American Society of Hematology (ASH) Annual Meeting, Benoit Tessoulin, MD, PhD, Head of the Lymphoma Department at the Nantes University Hospital in France, sat down with Oncology Data Advisor to discuss the results from the ELM-2 study in which the efficacy of odronextamab was investigated for maintaining functionality and quality of life in patients ...

Investigating Hypomethylating Agents for Myelodysplastic Syndromes With Amer Zeidan, MBBS, MHS

Oncology Data Advisor® · Investigating Hypomethylating Agents for Myelodysplastic Syndromes With Amer Zeidan Recently, at the American Society of Hematology (ASH) Annual Meeting, Amer Zeidan, MBBS, MHS, the Interim Chief of Hematologic Malignancies Division at the Yale Cancer Center, presented his abstract regarding an investigation of oral decitabine and cedazuridine versus intravenous/subcutaneous hypomethylating agents (HMA) for patients with myelodysplastic syndromes (MDS). In thi...

Lowering Talquetamab Dosing Intensity to Improve Tolerability With Ajai Chari, MD

Oncology Data Advisor® · Lowering Talquetamab Dosing Intensity to Improve Tolerability: Ajai Chari, MD At the recent American Society of Hematology (ASH) Annual Meeting, Ajai Chari, MD, Director of the Myeloma Program at the University of California, San Francisco, sat down with Oncology Data Advisor to discuss his abstract and presentation regarding updated results from the MonumenTAL-1 study and what to look forward to from the ever-evolving treatment landscape of multiple myeloma. ...